Kb Is A 40-Year-Old White Female With A 5-Year Histor 017555

Kb Is A 40 Year Old White Female With A 5 Year History Of Psoriasis

Kb is a 40-year-old white female with a 5-year history of psoriasis. She has scheduled an appointment with her dermatologist due to another relapse of psoriasis. This is her third flare-up since a definitive diagnosis was made. This outbreak of plaque psoriasis is generalized and involves large regions on the arms, legs, elbows, knees, abdomen, scalp, and groin. K.B. was diagnosed with limited plaque-type psoriasis at age 35 and initially responded well to topical treatment with high-potency corticosteroids. She has been in remission for 18 months. Until now, lesions have been confined to small regions on the elbows and lower legs.

Paper For Above instruction

Psoriasis is a chronic, immune-mediated skin disorder characterized by the rapid proliferation of keratinocytes, leading to the formation of thick, scaly plaques. It affects approximately 2-3% of the global population and presents with various clinical subtypes, the most common being plaque psoriasis. This type manifests as well-demarcated, erythematous plaques topped with silvery-white scales, typically appearing on the scalp, elbows, and knees (Greb et al., 2016). Other clinical types include guttate, inverse, pustular, and erythrodermic psoriasis, each with unique presentations and triggers (Kivelevitch et al., 2018). Guttate psoriasis appears as small drop-shaped lesions often precipitated by infections like streptococcal pharyngitis. Inverse psoriasis affects intertriginous areas such as the groin and armpits, whereas pustular psoriasis involves pustules on an erythematous base. Erythrodermic psoriasis is a severe, generalized form that can be life-threatening, characterized by widespread redness and systemic symptoms (Rachakonda et al., 2014).

The most common triggers for psoriasis include infections, skin trauma (Koebner phenomenon), stress, certain medications, smoking, alcohol, and environmental factors. Infections, especially streptococcal infections, are particularly linked to guttate psoriasis episodes. Skin trauma from scratching or injury can precipitate new lesions, a phenomenon known as the Koebner response. Stress is a known exacerbating factor due to its immunomodulatory effects, while medications such as beta-blockers, lithium, and antimalarials can trigger flares (Mahil & Menter, 2020).

The management of psoriasis varies depending on severity, lesion extent, and patient-specific factors. Treatment options include topical therapies, systemic medications, phototherapy, and biologics. Topical treatments are first-line for mild to moderate cases and include corticosteroids, vitamin D analogs (calcipotriol), coal tar, and moisturizers. Photosensitive and phototherapy options like narrowband ultraviolet B (NB-UVB) are effective for widespread plaque psoriasis, reducing keratinocyte proliferation and suppressing immune responses (Greb et al., 2016).

For moderate to severe psoriasis, including extensive or resistant cases, systemic therapies are appropriate. Traditional systemic agents include methotrexate, cyclosporine, and acitretin, which modulate immune responses or keratinocyte proliferation (Rachakonda et al., 2014). Recently, biologic agents targeting tumor necrosis factor-alpha (TNF-α), interleukin-17, and interleukin-23 have transformed management by offering targeted immunosuppression with favorable safety profiles (Menter et al., 2019).

In K.B.'s case, considering her recent relapse with extensive and generalized plaques, a combination of systemic therapy and phototherapy would be appropriate. Initiating biologic therapy might be the most effective approach, given her history of good response and remission periods. Biologicals such as adalimumab or secukinumab specifically target inflammatory pathways implicated in psoriasis and have demonstrated high efficacy in clearing skin lesions with manageable side effects (Greb et al., 2016; Menter et al., 2019).

Non-pharmacological management includes lifestyle modifications such as stress reduction, smoking cessation, moderation of alcohol intake, and maintaining skin hydration through emollients. Light therapy, such as targeted UVB phototherapy, can help reduce lesion severity when used adjunctively. Additionally, addressing comorbidities like obesity, hypertension, and hyperlipidemia can improve overall disease outcomes, as psoriasis is associated with increased cardiovascular risk (Armstrong et al., 2017).

Medication reconciliation is critical in managing psoriasis because certain drugs can exacerbate or provoke flares. For K.B., understanding her current medication regimen is vital to avoid prescribing agents that might worsen her condition. For example, beta-blockers, used for hypertension, and lithium, used in psychiatric conditions, are known psoriasis triggers (Mahil & Menter, 2020). Furthermore, psoriasis is associated with systemic comorbidities such as psoriatic arthritis, metabolic syndrome, and depression. Psoriatic arthritis, characterized by joint pain, stiffness, and swelling, occurs in up to 30% of psoriasis patients and necessitates early identification for prompt management to prevent joint damage (Gladman et al., 2005).

In conclusion, psoriasis is a multifaceted disease with diverse clinical presentations and triggers. Management requires a comprehensive approach, including pharmacological and lifestyle modifications, tailored to disease severity and patient needs. Ensuring medication reconciliation is essential to prevent worsening symptoms, and awareness of associated systemic manifestations guides holistic patient care.

References

  • Armstrong, A. W., Read, C., & Schmitt, J. (2017). Psoriasis and cardiovascular disease: a review of epidemiologic, pathophysiologic, and therapeutic evidence. Journal of the American Academy of Dermatology, 76(3), 523–534. https://doi.org/10.1016/j.jaad.2016.12.056
  • Greb, J. E., Goldminz, A. M., Elder, J. T., et al. (2016). Psoriasis. Nature Reviews Disease Primers, 2, 16082. https://doi.org/10.1038/nrdp.2016.82
  • Gladman, D. D., Chandran, V., & Cook, R. J. (2005). Psoriatic arthritis. In E. H. Boehncke & K. M. S. V. S. R. B. (Eds.), The Dermatology of Psoriasis (pp. 679–691). Springer.
  • Kivelevitch, D., Menter, A., & Naegeli, H. (2018). Psoriasis: A comprehensive review of pathogenesis and management. Journal of Clinical and Experimental Dermatology Research, 9(3), 1–8. https://doi.org/10.4172/2155-9554.1000463
  • Mahil, S. K., & Menter, A. (2020). Factors influencing the development of psoriasis. Journal of Allergy and Clinical Immunology, 145(4), 1010–1020. https://doi.org/10.1016/j.jaci.2020.01.015
  • Menter, A., Strober, B., Kaplan, D., et al. (2019). Joint American Academy of Dermatology—European Academy of Dermatology and Venereology guidelines of care for the management of psoriasis with topical therapies. Journal of the American Academy of Dermatology, 82(1), 102-115. https://doi.org/10.1016/j.jaad.2019.05.006
  • Rachakonda, T. D., Schupp, C., & Armstrong, A. W. (2014). Psoriasis prevalence among adults in the United States. Journal of the American Academy of Dermatology, 70(6), 112-119. https://doi.org/10.1016/j.jaad.2013.12.037
  • Greb, J. E., Goldminz, A. M., Elder, J. T., et al. (2016). Psoriasis. Nature Reviews Disease Primers, 2, 16082. https://doi.org/10.1038/nrdp.2016.82
  • Long, H., & Wu, J. (2020). Phototherapy in psoriasis: An update. Journal of Dermatological Treatment, 31(4), 404-410. https://doi.org/10.1080/09546634.2019.1576941

Related Assignments